Mutual Non-Disclosure Agreement
This Mutual Non-Disclosure Agreement (the “Agreement”) is made on (the “Effective Date”) between:
(1) Vitra Innovations Private Limited, a company incorporated under the Companies Act, 2013 (CIN U72900MH2020PTC343605), doing business as “BrandLabs”, with its office at B-108, Bhairav Shrusti, Opp. Maxus Mall, Bhayandar West, Thane 401101, Maharashtra, India (“BrandLabs”); and
(2) , a legal entity incorporated under the laws of (registration no. ), having its registered office atan individual (including a sole proprietor) residing atan individual residing at , signing in their own name for themself and for the business they are building under the name , which is not yet incorporated (the “Other Party”).
BrandLabs and the Other Party are each a “Party” and together the “Parties”. A Party that shares Confidential Information is the “Discloser” and a Party that receives it is the “Recipient”.
Background
(A) BrandLabs designs and builds private, safe AI and software for health and wellness companies.
(B) The Other Party is building, running or considering a health, healthcare or wellness product or business.
(C) The Parties want to talk about working together and expect to share confidential information in both directions. They agree as follows.
1. Purpose
1.1 The Parties are sharing Confidential Information only so that they can discuss, evaluate and, if both agree, negotiate a working relationship, namely: (the “Purpose”).
1.2 Neither Party has to share any particular information, and nothing in this Agreement obliges either Party to enter into any further agreement. Any engagement will happen only under a separate written agreement signed by both Parties.
2. What counts as Confidential Information
2.1 “Confidential Information” means all non-public information that the Discloser, or anyone acting on the Discloser's behalf, shares with the Recipient in connection with the Purpose, in any form (written, spoken, electronic, visual, or learned by inspecting a product, prototype, system or demo), whether shared before, on or after the Effective Date, that is marked confidential or that a reasonable person would understand to be confidential from its nature and the circumstances of sharing.
2.2 Without limiting clause 2.1, Confidential Information includes:
(a) business plans, strategy, finances, fundraising and investor information, pricing, customers, partners and pipeline;
(b) product ideas, designs, roadmaps, specifications, source code, algorithms, prompts and system prompts, models and model weights, training and evaluation datasets, test results and technical architecture;
(c) clinical and scientific material, such as clinical protocols, care pathways, content libraries, validation and study designs, and results;
(d) regulatory and compliance material, such as strategy and correspondence with health or data protection regulators, safety evaluation findings, audit reports, security vulnerabilities and incidents;
(e) the fact that the Parties are talking, and the terms of anything proposed between them; and
(f) notes, analyses and other material that the Recipient prepares and that contain or reflect any of the above.
2.3 “Personal Data” means information that relates to an identifiable individual, including information about that individual's health, treatment or wellbeing, and it also has any wider meaning given by data protection law that applies.
2.4 “Representatives” means a Party's directors, officers, employees, contractors and professional advisers (such as lawyers and accountants) who need to know Confidential Information for the Purpose. Investors, lenders and potential acquirers are not Representatives unless the Discloser first agrees in writing.
3. What is not Confidential Information
3.1 The obligations in this Agreement do not apply to information that the Recipient can show, by written records:
(a) is or becomes public without any breach of this Agreement;
(b) the Recipient already lawfully knew, free of any duty of confidence, before receiving it from the Discloser;
(c) the Recipient lawfully received from a third party who was free to share it; or
(d) the Recipient developed independently, without using or referring to the Confidential Information.
3.2 Information is not public, or already known, merely because parts of it are public or because more general information is public. A combination of features or items is not public unless the combination itself is.
3.3 None of these exclusions relieves a Party of its duties under clause 6 or under any law that applies to Personal Data.
4. How the Recipient will treat Confidential Information
4.1 Use only for the Purpose. The Recipient will use Confidential Information only for the Purpose, and not to build, improve or market any product or service, or to gain any commercial advantage for itself or anyone else.
4.2 Keep it confidential. The Recipient will not disclose Confidential Information to anyone except its Representatives. Before sharing with a Representative, the Recipient will make sure that person is bound by a duty of confidence (by contract, employment terms or professional duty) at least as protective as this Agreement. The Recipient is responsible for anything a Representative does or fails to do that would breach this Agreement if the Recipient had done it.
4.3 Take proper care. The Recipient will protect Confidential Information with at least the care it gives its own most sensitive information, and never less than reasonable care. That includes sensible technical and organisational safeguards: access limited to people who need it, strong authentication, encryption of electronic copies in transit and at rest, and no storage on unmanaged personal devices or accounts.
4.4 Copies and reverse engineering. The Recipient will make only the copies reasonably needed for the Purpose. The Recipient will not reverse engineer, decompile or disassemble any software, model, prototype or sample the Discloser provides, or try to extract source code, prompts, model weights or training data from it.
4.5 Tell the Discloser quickly. If the Recipient becomes aware of any unauthorised access to, or use or disclosure of, the Discloser's Confidential Information, the Recipient will tell the Discloser in writing without undue delay and in any case within 72 hours, share the details it has, and help to contain and fix the problem.
4.6 Keep the talks private. Neither Party will tell anyone outside its Representatives that the Parties are in discussions, or use the other Party's name, logo or trademarks (including by listing the other as a client, partner or investee), without the other Party's prior written consent. Email is enough.
5. Artificial intelligence tools
5.1 The Recipient will not put the Discloser's Confidential Information into any AI system, large language model, chatbot, coding assistant, transcription or note-taking tool, or similar automated service (an “AI Tool”) unless both of the following are true:
(a) the AI Tool is run by the Recipient, or by a provider under written terms that stop the provider from using inputs or outputs to train or improve its models, and from keeping them beyond what is needed to run and secure the service and to comply with the law; and
(b) only the Recipient's Representatives who need to know can use it for this purpose.
5.2 The Recipient will not use the Discloser's Confidential Information to train, fine-tune or benchmark any AI model, unless the Parties agree otherwise in writing.
5.3 Using an AI Tool in line with clause 5.1 counts as sharing with a Representative, so the Recipient stays responsible for it.
6. Personal Data and health data
6.1 No Personal Data by default. The Parties do not intend to share Personal Data under this Agreement. Neither Party will give the other any Personal Data, including patient, user, member or employee records and health information that identifies or could reasonably identify someone, unless the Parties have first signed a separate written agreement that covers it, such as a data processing agreement and, where it applies, a business associate agreement or its equivalent.
6.2 Sample data. If the Parties need realistic data to talk or to test, they will use synthetic data, or data that has been properly de-identified or anonymised so that it cannot reasonably be traced back to a person. The Discloser is responsible for making sure that standard is met.
6.3 If it happens by mistake. If Personal Data is shared in breach of clause 6.1, the Recipient will stop using it, will not copy it, will tell the Discloser without undue delay, and will securely delete or return it as the Discloser reasonably instructs, unless the law requires it to be kept. The Recipient will comply with the data protection and health information laws that apply to it, which may include the Digital Personal Data Protection Act, 2023 and the Information Technology Act, 2000 of India, HIPAA in the United States and the GDPR in the European Union and United Kingdom.
6.4 Own compliance. Each Party stays responsible for its own compliance with data protection and health information law. This Agreement does not make either Party the other's data processor, data fiduciary, business associate or similar.
7. Disclosure required by law
7.1 If the law, a court or a regulator requires the Recipient to disclose Confidential Information, the Recipient may do so only if, as far as the law allows, it (a) gives the Discloser prompt written notice so that the Discloser can seek a protective order or other remedy, (b) cooperates reasonably with that effort at the Discloser's cost, and (c) discloses only the part that it is legally required to disclose. The information stays confidential for every other purpose.
8. Ownership, no licence and no residuals
8.1 Ownership. Confidential Information stays the property of the Discloser or its licensors. This Agreement gives the Recipient no licence or right in the Discloser's patents, copyrights, trade secrets, trademarks or other intellectual property, other than the limited right to use Confidential Information for the Purpose.
8.2 Right to share, and no warranty. Each Party confirms that it has the right to share the Confidential Information it shares and that doing so does not breach any duty it owes to someone else. Otherwise, Confidential Information is shared as is, with no warranty of accuracy or completeness.
8.3 No residuals. Neither Party may use or disclose Confidential Information on the ground that it was remembered after reviewing it. This Agreement has no “residuals” clause.
8.4 Independent work. Each Party, including BrandLabs, which works with many health and wellness companies, may develop, acquire or work on products and services that are similar to or compete with the other Party's, as long as it does not use or disclose the other Party's Confidential Information in doing so.
9. Term and how long confidentiality lasts
9.1 This Agreement starts on the Effective Date. Confidential Information may be shared for 2 years from the Effective Date (the “Sharing Period”). Either Party may end the Sharing Period earlier at any time by written notice to the other. Email is enough.
9.2 The Recipient's duties continue for 5 years after the Sharing Period ends. For trade secrets, including source code, prompts, model weights and training data, they continue for as long as the information remains a trade secret other than through a breach. For Personal Data, they continue for as long as the Recipient holds it or the law requires.
9.3 Ending or expiry does not affect rights or liabilities that have already arisen. Clauses 4 to 8 and 10 to 14 survive for as long as they are needed to give effect to this clause 9.
10. Return and deletion
10.1 Within 14 days after the Discloser asks in writing, which it may do at any time, the Recipient will return or securely delete all of the Discloser's Confidential Information, including copies and the Recipient's own notes that contain it, and will confirm by email that it has done so.
10.2 The Recipient may keep (a) copies in routine electronic backups until they are overwritten in the ordinary course, and (b) copies that the law, a regulator or a professional obligation requires it to keep. Anything kept stays confidential under this Agreement for as long as it is kept and may not be used for any other purpose.
10.3 Returning or deleting Confidential Information does not end the Recipient's other duties under this Agreement.
11. Remedies
11.1 The Parties agree that unauthorised use or disclosure of Confidential Information could cause harm that money alone would not repair. The Discloser may therefore ask a court or arbitrator for an injunction or other urgent relief without having to prove actual loss, in addition to any other remedy available.
12. No obligation and no partnership
12.1 Neither Party has to proceed with any transaction, neither Party is exclusive to the other, and each Party bears its own costs. Nothing in this Agreement creates a partnership, joint venture, agency, employment or fiduciary relationship, and neither Party can bind the other.
12.2 The individual named as the Other Party is bound by this Agreement personally. Once the business is incorporated, that individual will tell BrandLabs, and on a short written confirmation signed by the new company it will be added as a Party. The individual stays bound for everything shared before then.
13. Governing law and disputes
13.1 This Agreement is governed by the laws of India.
13.2 Talk first. If a dispute arises, one Party will give the other written notice of it, and the Parties will try in good faith to settle it through their senior representatives within 30 days. Either Party may seek urgent relief under clause 11 at any time.
13.3 Arbitration. A dispute not settled in that time will be finally resolved by arbitration under the Arbitration and Conciliation Act, 1996, as amended, by a sole arbitrator appointed by agreement of the Parties or, if they do not agree within 15 days of a request, appointed in accordance with that Act. The seat and venue of the arbitration is Mumbai, the language is English, and the award is final and binding and may be enforced in any court that has jurisdiction.
13.4 Courts. Subject to clause 13.3, the courts at Mumbai have exclusive jurisdiction over interim relief in aid of arbitration and over enforcement of an award.
14. General
14.1 Whole agreement. This is the whole agreement between the Parties about the confidentiality of information shared for the Purpose, and it replaces earlier discussions about it. If the Parties later sign a services or other agreement, this Agreement keeps applying to Confidential Information shared before that agreement, unless that agreement says expressly that it replaces this one.
14.2 Changes and waiver. A change to this Agreement must be in writing and signed by both Parties. Electronic signature is fine. Delay or failure to enforce a right is not a waiver of it.
14.3 If part is unenforceable. If any part of this Agreement cannot be enforced, the rest stays in force, and the part that cannot be enforced is limited to the minimum extent needed, or replaced with a valid provision that is as close as possible to the original intent.
14.4 Assignment. Neither Party may assign or transfer this Agreement, or any right under it, without the other Party's prior written consent. The exception is a transfer to the successor of all or substantially all of a Party's business, who agrees in writing to be bound by this Agreement, after telling the other Party.
14.5 Notices. Notices under this Agreement must be in writing and sent by email to the receiving Party's address in the signature block below, or to another address that Party has given by email. A notice is received when it is sent, unless the sender gets a message that it was not delivered.
14.6 Signing electronically. The Parties may sign in counterparts, by hand or by electronic signature, including a signed scan or PDF. Electronic signatures are valid and binding under the Information Technology Act, 2000, and the counterparts together form one agreement.
14.7 Stamp duty. BrandLabs will bear the stamp duty payable on this Agreement under applicable law and will arrange for it to be stamped when that is needed.
14.8 Authority. Each person signing confirms that they are authorised to sign for the Party named beside their signature or, for an individual, in their own name.
14.9 Reading this Agreement. Headings are for convenience only. “Including” means including without limitation. “Written” and “in writing” include email. This Agreement is in English.
Signed by the Parties on the dates below.
| For Vitra Innovations Private Limited (BrandLabs) | For |
|---|---|
| Signature: | Signature: |
| Name: Harsh Vitra | Name: |
| Designation: Founder | Designation: |
| Email for notices: contact@brandlabs.app | Email for notices: |
| Date: ____________ | Date: ____________ |
BrandLabs Mutual NDA · template version 1.0 · brandlabs.app/legal/mutual-nda